## Abstract ## BACKGROUND. Despite recommendations to immunize all patients at an increased risk of influenza complications, the vaccine utilization among high‐risk nonelderly adults remains low and its cost‐effectiveness is unclear. In the current study, the authors analyzed the cost‐effectivenes
Failure of influenza vaccination in the aged
✍ Scribed by Gershon Keren; Shlomo Segev; Abraham Morag; Zichria Zakay-Rones; Asher Barzilai; Ethan Rubinstein
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 303 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
A cohort of 127 nursing home residents aged 60-98 years were vaccinated during the winter of 1985-86 with the A-Chile 1/83 (C), A-Philippines 2/82 (P), and B-USSR (B) commercial influenza vaccines. Before vaccination 40%, 23%, and 69% were susceptible to influenza Ac, Ap, and B, respectively [hemagglutinin inhibition (H.I.) titer less than 1:40]. One month following initial vaccination, 32 patients [25%] remained unprotected against two or all three vaccine strains. These patients were revaccinated with the same influenza vaccine and followed up. At five months 11%, 19%, and 23% of the initial cohort were still unprotected against Ac, Ap, and B strains, respectively. We conclude that two conventional influenza vaccines administered one month apart leave unprotected 30% of healthy elderly people who are initial influenza vaccine failures.
📜 SIMILAR VOLUMES
To assess the efficacy of influenza vaccination in immunocompromised adult liver transplant (LTx) recipients, the serum antibody responses of 61 of these patients and 35 liver cirrhosis patients with those of 45 of their healthy spouses were compared, after one and two vaccinations with a commercial
## Abstract The levels and properties of neutralizing antibodies in nasal wash and serum collected from five healthy adults were examined after intranasal administration of an A/Uruguay/716/2007 (H3N2) split vaccine (45 µg hemagglutinin (HA) per dose; five doses, with an interval of 3 weeks between
Background: Protection against vaccine-preventable diseases is important in inflammatory bowel disease (IBD) because of increased susceptibility and severity of infection with immunosuppressive therapy. However, immunosuppressive therapy may affect vaccine response. This study aimed to evaluate immu
## Abstract In a small pilot study, sera from 10 healthy human volunteers were taken pre‐vaccine, then 1, 3, and 6 months post‐seasonal influenza immunization (using the 2005/2006 Northern hemisphere vaccine: A/New Caledonia/20/99(H1N1)‐like, A/California/7/2004(H3N2)‐like, and B/Shanghai/361/2002‐